Table 4.
Treatment group | Tumour weight (g) | Tumour inhibition ratio | Viable tumour cell count (107 cells/mL) | Non-viable tumour cell count (107 cells/mL) | Average survival time (d) | Increase in life spanb (%) |
---|---|---|---|---|---|---|
Group II (EAC) | 5.10 ± 0.46 | – | 9.97 ± 0.92 | 1.04 ± 0.35 | 25.4 ± 2.40 | – |
Group III (EAC + DLG) | 3.47 ± 0.25a | 0.32a | 5.18 ± 0.25a | 2.37 ± 0.22a | 49.6 ± 8.80a | 95.30 |
Group IV (EAC + 2-DG) | 3.99 ± 0.22a | 0.22a | 6.35 ± 0.33a | 1.61 ± 0.17a | 40.2 ± 9.00a | 58.30 |
Group V (EAC + DLG + 2-DG) | 2.36 ± 0.20* | 0.54a | 4.31 ± 0.2a | 3.50 ± 0.25a | 62.4 ± 7.70a | 145.70 |
Results are mean ± SD; n = 10
aStatistically significant with p < 0.01, and when EAC control (group II) compared with the treated group
bPercentage increase over group II